Dihexa
Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Key Facts: Dihexa
- Category
- Cognitive
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - Research compound
- Administration
- Oral, sublingual, or intranasal
- Typical Dose
- 5-20 mg oral or sublingual daily
- Frequency
- Once daily, effects can last up to 10 days
- Evidence Level
- Animal Studies
- Duration
- Cycles of 2-4 weeks
What to Expect
A potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
Mechanism of Action
Dihexa activates hepatocyte growth factor (HGF) signaling through the c-Met receptor. This promotes dendritic spine formation, enhances synaptic connections, and supports neuronal survival. Crosses blood-brain barrier orally.
Research Summary
Animal studies show remarkable cognitive enhancement and reversal of scopolamine-induced memory deficits. Research demonstrates increased dendritic spine density. Limited human data but significant interest in nootropic community.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
5-20 mg oral or sublingual daily
5-40 mg daily (some report up to 80 mg)
Once daily, effects can last up to 10 days
Orally bioavailable (38% absorption). Crosses blood-brain barrier. Cycle 90 days on, 30 days off recommended. CAUTION: Activates c-Met pathway which may promote cancer cell growth - avoid if history of cancer. Failed clinical trials; no human safety data. Start low (5 mg) to assess tolerance.
Research Dosingⓘ
Scientific studies
Doses from research/anecdotal use
Doses from Studies
10-20 mg oral or sublingual
5-10 mg intranasal
Duration
Cycles of 2-4 weeks
Administration
Oral, sublingual, or intranasal
Timing & Administration
Best Time to Take
Morning
Once daily in the morning
Food Recommendation
With or without food
Why This Timing?
Dihexa supports cognitive function and memory. Morning dosing aligns with peak cognitive demands.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nervousness
- ●Headache
- ●Anxiety
- ●Insomnia
- ●Nausea
- ●Potential bleeding problems
- ●Concerns about tumor development
- ●NO human clinical trials
References
Related Peptides
Peptides commonly compared with Dihexa or used in similar applications.
Selank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveSemax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
CognitiveCerebrolysin
Clinical TrialsA mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
CognitiveGB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia and currently in clinical trials for anxiety and cognitive enhancement. Users report significant improvements in focus, attention, and ADHD-like symptoms.
CognitiveP21
PreclinicalA synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.
CognitiveARA-290
Clinical TrialsAn 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
CognitiveWant updates on Dihexa research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.